Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

38.97
-0.0100-0.03%
Volume:383.67K
Turnover:14.88M
Market Cap:3.66B
PE:-6.20
High:39.25
Open:39.00
Low:37.89
Close:38.98
Loading ...

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE + RARE DISEASE DAY AWARENESS

PR Newswire
·
28 Feb

Ultragenyx Pharma Price Target Maintained With a $118.00/Share by Cantor Fitzgerald

Dow Jones
·
26 Feb

Ultragenyx to Participate at Investor Conferences in March

GlobeNewswire
·
25 Feb

Analysts Offer Insights on Healthcare Companies: Icon (ICLR), Pediatrix Medical Group (MD) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
23 Feb

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.
·
22 Feb

BRIEF-Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
20 Feb

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
20 Feb

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
20 Feb

Ultragenyx Pharma Price Target Maintained With a $95.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Feb

Optimistic Outlook for Ultragenyx Pharmaceutical Amid Promising Gene Therapy Developments

TIPRANKS
·
19 Feb

Ultragenyx Pharmaceutical Shares up 1.7% as FDA Accepts Genetic Disorder Therapy for Review

THOMSON REUTERS
·
19 Feb

Ultragenyx Pharmaceutical Eyes Aug. 18 FDA Approval for Sanfilippo Syndrome Gene Therapy Treatment

MT Newswires Live
·
18 Feb

Ultragenyx’s BLA for UX111 accepted by FDA for priority review

TIPRANKS
·
18 Feb

Ultragenyx Pharmaceutical Inc - FDA Not Planning Advisory Committee Meeting for Ultragenyx Bla

THOMSON REUTERS
·
18 Feb

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (Bla) for Ux111 Aav Gene Therapy to Treat Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
18 Feb

Ultragenyx Pharmaceutical Inc - FDA Grants Priority Review for Ultragenyx Bla With Pdufa Date Aug 18, 2025

THOMSON REUTERS
·
18 Feb

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewswire
·
18 Feb

Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating

TIPRANKS
·
17 Feb

Evercore ISI Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
17 Feb

Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Feb